Announcements Trials
Browse Landscape

Phase

Phase 2 38Phase 1/2 6Phase 3 4Phase 1 3Phase 2/3 2Phase NA 1

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Other hematologic neoplasm 1Lymphoid 1Head & Neck 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Head and Neck Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cisplatin 98Gemcitabine 66Paclitaxel 62Carboplatin 60Fluorouracil 59Docetaxel 59Capecitabine 59Oxaliplatin 56Cyclophosphamide 54Radiotherapy 50Drug Therapy 46Bevacizumab 38pembrolizumab 35Dexamethasone 33Magnetic Resonance Spectroscopy 32Leucovorin 32Doxorubicin 31Cytarabine 27Etoposide 26Pemetrexed 25Nivolumab 24Methotrexate 24Radiation 20Vincristine 18venetoclax 17apatinib 17Rituximab 17Prednisone 17Letrozole 17Irinotecan 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × ponatinib × Clear all
NCT06860269 2026-02-10

GRAALL-2024

Assistance Publique - Hôpitaux de Paris

Phase 2/3 Recruiting
1,200 enrolled
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01761747 2014-12-23

Ponatinib for Squamous Cell Lung and Head and Neck Cancers

Dana-Farber Cancer Institute

Phase 2/3 Terminated
3 enrolled 9 charts
Head & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡